Refractory Multiple Myeloma: 1559 Clinical Trials, Page 45 of 156

Hide Studies Not Open or Pending

446

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasms; Gammopathy, Monoclonal; Paraproteinemias; Blood Protein Disorders; Haematologic Disease; Corneal Disease; Neoplasms, Plasma CellLast Updated:October 17, 2022Not yet recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.